biotech · Sleep · T-Cell Acute Lymphoblastic Leukemia/Lymphoma · BEAM
Beam Therapeutics
Beam Therapeutics clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2017
- Employees
- 573
- Programs
- 10
- Drugs
- 14
- Patents
- 14
Beam Therapeutics projects
5 ClinicalTrials.gov programs sponsored by Beam Therapeutics.
Beam Therapeutics has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
BEAM-101
Beam Therapeutics
Sickle Cell Disease
1 trial -
BEAM-201
Beam Therapeutics
Lymphoblastic Lymphoma
1 trial -
BEAM-301: Single dose of BEAM-301 administered by IV
Beam Therapeutics
Glycogen Storage Disease Type Ia
1 trial -
BEAM-302
Beam Therapeutics
Alpha 1-Antitrypsin Deficiency
1 trial -
BEAM-302
Beam Therapeutics
Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease and/or Liver Disease
1 trial
Frequently asked questions
How many clinical projects does Beam Therapeutics have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.